JP2022548957A5 - - Google Patents

Info

Publication number
JP2022548957A5
JP2022548957A5 JP2022517933A JP2022517933A JP2022548957A5 JP 2022548957 A5 JP2022548957 A5 JP 2022548957A5 JP 2022517933 A JP2022517933 A JP 2022517933A JP 2022517933 A JP2022517933 A JP 2022517933A JP 2022548957 A5 JP2022548957 A5 JP 2022548957A5
Authority
JP
Japan
Prior art keywords
mrna
nucleic acid
isolated nucleic
rnase
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022517933A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022548957A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/051583 external-priority patent/WO2021055811A1/en
Publication of JP2022548957A publication Critical patent/JP2022548957A/ja
Publication of JP2022548957A5 publication Critical patent/JP2022548957A5/ja
Pending legal-status Critical Current

Links

JP2022517933A 2019-09-19 2020-09-18 キャップガイド及びrnaマッピングのためのその使用方法 Pending JP2022548957A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962902604P 2019-09-19 2019-09-19
US62/902,604 2019-09-19
PCT/US2020/051583 WO2021055811A1 (en) 2019-09-19 2020-09-18 Cap guides and methods of use thereof for rna mapping

Publications (2)

Publication Number Publication Date
JP2022548957A JP2022548957A (ja) 2022-11-22
JP2022548957A5 true JP2022548957A5 (cg-RX-API-DMAC7.html) 2023-09-28

Family

ID=74884727

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022517933A Pending JP2022548957A (ja) 2019-09-19 2020-09-18 キャップガイド及びrnaマッピングのためのその使用方法

Country Status (6)

Country Link
US (1) US20220349006A1 (cg-RX-API-DMAC7.html)
EP (1) EP4031666A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022548957A (cg-RX-API-DMAC7.html)
AU (1) AU2020348860A1 (cg-RX-API-DMAC7.html)
CA (1) CA3155014A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021055811A1 (cg-RX-API-DMAC7.html)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20220070T1 (hr) 2014-04-23 2022-04-01 Modernatx, Inc. Cjepiva nukleinske kiseline
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
EP3328394A4 (en) 2015-07-30 2019-03-13 ModernaTX, Inc. CONCATEMEE peptide epitope RNAs
WO2017031232A1 (en) 2015-08-17 2017-02-23 Modernatx, Inc. Methods for preparing particles and related compositions
DE20164728T1 (de) 2015-10-22 2021-09-30 Modernatx, Inc. Impfstoffe gegen atemwegsvirus
EP3364949A4 (en) 2015-10-22 2019-07-31 ModernaTX, Inc. CANCER VACCINES
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
EP3364981A4 (en) 2015-10-22 2019-08-07 ModernaTX, Inc. VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
SG11201803360UA (en) 2015-10-22 2018-05-30 Modernatx Inc Nucleic acid vaccines for varicella zoster virus (vzv)
DK3386484T3 (da) 2015-12-10 2022-07-04 Modernatx Inc Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler
US12128113B2 (en) 2016-05-18 2024-10-29 Modernatx, Inc. Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome
SG11201901941YA (en) 2016-09-14 2019-04-29 Modernatx Inc High purity rna compositions and methods for preparation thereof
EP3528821A4 (en) 2016-10-21 2020-07-01 ModernaTX, Inc. HUMAN CYTOMEGALOVIRUS VACCINE
MA46766A (fr) 2016-11-11 2019-09-18 Modernatx Inc Vaccin antigrippal
EP3555289A1 (en) 2016-12-13 2019-10-23 ModernaTX, Inc. Rna affinity purification
WO2018170260A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Respiratory syncytial virus vaccine
US11576961B2 (en) 2017-03-15 2023-02-14 Modernatx, Inc. Broad spectrum influenza virus vaccine
WO2018170256A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Herpes simplex virus vaccine
WO2018170270A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
WO2018170347A1 (en) 2017-03-17 2018-09-20 Modernatx, Inc. Zoonotic disease rna vaccines
MA48047A (fr) 2017-04-05 2020-02-12 Modernatx Inc Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée
MA49421A (fr) 2017-06-15 2020-04-22 Modernatx Inc Formulations d'arn
WO2019036685A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. METHODS FOR HPLC ANALYSIS
WO2019036682A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. RNA VARIANTS POLYMERASE
EP3668977A4 (en) 2017-08-18 2021-04-21 Modernatx, Inc. HPLC ANALYTICAL PROCESSES
MX2020002348A (es) 2017-08-31 2020-10-08 Modernatx Inc Métodos de elaboración de nanopartículas lipídicas.
EP3681514A4 (en) 2017-09-14 2021-07-14 ModernaTX, Inc. RNA VACZINE AGAINST ZIKA VIRUS
US11911453B2 (en) 2018-01-29 2024-02-27 Modernatx, Inc. RSV RNA vaccines
US12151029B2 (en) 2018-09-19 2024-11-26 Modernatx, Inc. PEG lipids and uses thereof
CN112996854B (zh) 2018-09-19 2024-08-30 摩登纳特斯有限公司 高纯度peg脂质和其用途
US12090235B2 (en) 2018-09-20 2024-09-17 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
CN113939282A (zh) 2019-01-31 2022-01-14 摩登纳特斯有限公司 制备脂质纳米颗粒的方法
US11851694B1 (en) 2019-02-20 2023-12-26 Modernatx, Inc. High fidelity in vitro transcription
MX2021010075A (es) 2019-02-20 2021-12-10 Modernatx Inc Variantes de arn polimerasa para la formacion de casquetes cotranscripcionales.
MX2021011031A (es) 2019-03-11 2021-12-10 Modernatx Inc Proceso de transcripción in vitro en lotes alimentados.
MA55321A (fr) 2019-03-15 2022-01-19 Modernatx Inc Vaccins à base d'arn contre le vih
CN118490818A (zh) 2020-04-22 2024-08-16 生物技术欧洲股份公司 冠状病毒疫苗
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
WO2022150717A1 (en) 2021-01-11 2022-07-14 Modernatx, Inc. Seasonal rna influenza virus vaccines
JP2024512780A (ja) * 2021-04-01 2024-03-19 モデルナティエックス インコーポレイテッド 多価rna組成物中のrna種の識別及び比率決定のための方法
EP4326227A1 (en) 2021-04-23 2024-02-28 ModernaTX, Inc. Stabilized formulations
US20220363937A1 (en) 2021-05-14 2022-11-17 Armstrong World Industries, Inc. Stabilization of antimicrobial coatings
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
US12529047B1 (en) 2021-12-21 2026-01-20 Modernatx, Inc. mRNA quantification methods
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
KR20260025139A (ko) * 2023-06-14 2026-02-23 사노피 백신즈 유에스 인크. 메신저 rna의 캡핑 및 테일링 변형을 동시에 식별하거나 정량화하는 방법
US12553042B2 (en) 2023-12-01 2026-02-17 Recode Therapeutics, Inc. Method for quantifying an amount of capped messenger RNA

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346614B1 (en) * 1992-07-23 2002-02-12 Hybridon, Inc. Hybrid oligonucleotide phosphorothioates
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
US5684143A (en) 1996-02-21 1997-11-04 Lynx Therapeutics, Inc. Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US20160032273A1 (en) * 2013-03-15 2016-02-04 Moderna Therapeutics, Inc. Characterization of mrna molecules
CA2969619A1 (en) * 2014-12-03 2016-06-09 Agilent Technologies, Inc. Guide rna with chemical modifications
WO2017098468A1 (en) * 2015-12-09 2017-06-15 Novartis Ag Label-free analysis of rna capping efficiency using rnase h, probes and liquid chromatography/mass spectrometry
MA46643A (fr) 2016-10-26 2019-09-04 Modernatx Inc Méthodes et compositions pour le mappage d'arn
CN111225975A (zh) * 2017-09-11 2020-06-02 加利福尼亚大学董事会 抗体介导的cas9向哺乳动物细胞的递送

Similar Documents

Publication Publication Date Title
AU2021266291B2 (en) Allele-specific amplification using a composition of overlapping non-allele-specific primer and allele-specific blocker oligonucleotides
JP2005503802A5 (cg-RX-API-DMAC7.html)
EP2580355A4 (en) A REVERSE TRANSCRIPTION AND THROUGH BASE-SPACING RESTRICTED QUANTITATIVE PCR PROVIDED THROUGH AN OLIGONUCLEOTIDE WITH A CHANGED HAIR NEEDLE STRUCTURE
JP2012531202A5 (cg-RX-API-DMAC7.html)
BR0214741A (pt) Iniciador de controle de anelamento para melhorar a especificidade de anelamento na amplificação de ácido nucléico, kit, métodos para amplificar uma sequência de ácido nucléico de um dna ou uma mistura de ácidos nucléicos, e para amplificar seletivamente uma sequência de ácido nucléico alvo de um dna ou uma mistura de ácidos nucléicos, e uma sequência de ácido nucléico alvo a partir de um mrna, método para detectar a complementaridade de dna ao mrna diferencialmente expresso em duas ou mais amostras de ácido nucléico, métodos para amplificar rapidamente um fragmento de cdna e dna alvo, e para amplificar uma população de cdnas de filamento duplo de comprimento completo complementar aos mrnas, e cdnas de filamento duplo enriquecidos em 5' complementares aos mrnas, método para amplificar mais do que uma sequência de nucleotìdeo alvo simultaneamente, métodos para produzir uma impressão digital de dna de gdna, e de rna de uma amostra de mrna, método para identificar segmentos de homologia conservada em uma famìlia de multigene a partir de uma amostra de mrna, método para a mutagênese em um ácido nucléico alvo, e, uso do iniciador
KR890701764A (ko) 표적 뉴클레오티드 서열의 선택적 증식
JP2015523864A5 (cg-RX-API-DMAC7.html)
CN101638685A (zh) 交叉引物扩增靶核酸序列的方法及用于扩增靶核酸序列的试剂盒及其应用
JP2009035530A5 (cg-RX-API-DMAC7.html)
WO2010090857A8 (en) Methods for amplifying hepatitis c virus nucleic acids
AU2011230496A8 (en) Methods for enhancing nucleic acid hybridization
JP2013513360A5 (cg-RX-API-DMAC7.html)
EP2126120A1 (en) Assay for gene expression
JP2011501663A5 (cg-RX-API-DMAC7.html)
EP2653559A1 (en) Polynucleotide and use thereof
US20100255546A1 (en) Nucleic acid amplification method
JP4931595B2 (ja) Rna配列の増幅のための方法
JP2015097529A (ja) 核酸増幅用プライマーの設計方法、核酸増幅用プライマーの製造方法、核酸増幅用プライマー、プライマーセット、および核酸の増幅方法
CN110651050A (zh) 用于检测低频突变的靶向富集方法和试剂盒
EP3286331A1 (en) Method for hybridizing a nucleic acid molecule
JP2018500936A5 (cg-RX-API-DMAC7.html)
JPWO2023013613A5 (cg-RX-API-DMAC7.html)
WO2008093283A3 (en) Use of double stranded rna hairpin duplexes in gene silencing
JP7306722B2 (ja) プライマー及びその使用
JP2006345800A5 (cg-RX-API-DMAC7.html)